" class="no-js "lang="en-US"> Catherine Stehman-Breen - Medtech Alert
Saturday, September 13, 2025

Breaking News

Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Astellas and Cullgen Enter into Strategic Collaboration and Option Agreement to Advance Innovative Targeted Protein Degraders Auxilius Pharma Raises Seed Funding of $1 Million and Commences its Clinical Program Captivate Bio and EverCell Bio partner on Human Cell Modeling Services for Cell and Gene Therapy Markets Applied StemCell Partners with CIRM to Provide Clinical-Grade iPSCs and Access to Its Proprietary Gene Editing Technologies Alentis Therapeutics Receives IND Clearance from FDA for ALE.C04 for the Treatment of CLDN1+ Tumors
Catherine Stehman-Breen

Catherine Stehman-Breen

About Catherine Stehman-Breen

Highly experienced biopharmaceutical executive and physician-scientist with 15+
years of industry experience. Significant success in building and leading high performing teams with broad organizational impact.

Related Story

Fundraising

 Chroma Medicine Secures $135M in Series B Financing to Advance Breakthrough Epigenetic Editing Technology | MTA

Chroma Medicine Secures $135M in Series B Financing to Advance Breakthrough Epigenetic Editing Technology

March 1 2023

Chroma Medicine, a genomic medicine company pioneering single-dose epigenetic editing therapeutics, today announced the completion […]

Fundraising

 Chroma Medicine Launches with $125M in Financing to Deliver on the Promise of Epigenetic Editing | Pharmtech Focus

Chroma Medicine Launches with $125M in Financing to Deliver on the Promise of Epigenetic Editing

November 17 2021

Chroma Medicine, Inc., (Chroma) a new genomic medicine company pioneering epigenetic editing, launched today with $125M in […]